Articles tagged with Muscular Dystrophy
A team of researchers from Université Laval has proven that it is possible to repair the defective gene responsible for Duchenne muscular dystrophy. They developed enzymes called meganucleases that can correct the dystrophin gene and restore its expression in muscle cells.
A new study aims to investigate whether erectile dysfunction drugs can improve muscle blood flow and reduce fatigue in muscular dystrophy patients. The research, led by Ronald G. Victor, will test the effects of tadalafil on muscle blood flow during exercise in adult males with Becker muscular dystrophy.
A chemical called a molecular band-aid has been discovered to protect the hearts of Duchenne muscular dystrophy patients by preventing heart injury and remodeling. The treatment, which requires repeated injections, showed significant promise in a canine model, paving the way for potential human trials.
A new therapy has been found to prevent severe cardiac injury and ventricular dilatation in dogs with muscular dystrophy. The treatment, which involves chronic infusion of a membrane-sealing agent, restores the compliance of heart muscles from dystrophic dogs to normal.
A study published in Nature Structural & Molecular Biology reveals that a genetic mutation disrupts an array of metabolic pathways in muscle cells by affecting two key proteins. The loss of either protein accounts for most molecular abnormalities associated with the disease, while loss of both also seems to play an important role.
Researchers have identified a new form of adult-onset muscular dystrophy caused by recessive ANO5 mutations, which lead to abnormal membrane repair of muscle fibers. This discovery may lead to better treatments for all muscular dystrophies where such abnormalities play a role.
A University of Iowa study reveals a critical link in the sugar chain of an important muscle protein, providing insights into congenital muscular dystrophies and cancer progression. The discovery may lead to new therapies for treating these conditions.
A study demonstrates the effectiveness of a gene delivery strategy producing follistatin, which inhibits myostatin, in non-human primates, showing pronounced increases in muscle size and strength. The treatment is well-tolerated and has long-term effects, paving the way for potential clinical trials.
Researchers at the University of Oregon and University of Rochester discovered a compound that reverses genetic defects in RNA leading to type 1 myotonic dystrophy. The compound, pentamidine, disrupts complexes formed by expanded repeats and protein molecules, allowing proper splicing errors to be rescued.
Mutations in the PTRF gene have been found to cause a form of muscular dystrophy with generalized lipodystrophy. The disease is characterized by progressive skeletal muscle weakness and deficiency of caveolin-3 protein.
Duchenne muscular dystrophy patients lack the protein dystrophin, which protects muscle cells by connecting to filament types. The new study reveals microtubules become disorganized when dystrophin is missing, contributing to devastating symptoms.
A new study identifies alpha dystroglycan as a key protein that binds muscle membranes to the basal lamina, reinforcing membrane integrity. Injecting functional dystroglycan into muscle tissue restored membrane integrity and protected muscles from damage.
Researchers found a synthetic molecule that breaks up deposits of toxic genetic material and re-establishes cellular activity disrupted by myotonic dystrophy. The treatment could restore muscle function in people with the disease.
Scientists have made significant discoveries in the fight against muscular dystrophy, identifying a potential gene therapy approach to overexpress Galgt2 protein. In another breakthrough, researchers have identified a stromal marker for breast cancer progression, highlighting the importance of examining stroma PDGF receptor expression ...
A team of researchers used mice as model animals to study the key proteins involved in two types of muscular dystrophy. They found disrupted stem cell function and delays of skeletal muscle formation in embryos of MD-like mice, suggesting that both types of MD might be detected in utero or shortly after birth.
Researchers have discovered a new therapy that substitutes the missing protein dystrophin to repair weakened muscle tissue in mouse models with Duchenne muscular dystrophy. The TAT-utrophin-based protein approach addresses the cause of the disease without gene replacement or stem cell issues, offering a potential treatment option.
Boys with Duchenne Muscular Dystrophy symptoms show signs for over a year before diagnosis and disease-specific treatment, highlighting the need for early detection and intervention. A simple and inexpensive blood test could accelerate this process, enabling timely treatment and improving outcomes.
The March of Dimes has awarded a $250,000 prize to Kevin P. Campbell and Louis M. Kunkel for their pioneering work identifying the genes and proteins that cause muscular dystrophy. Their research has led to better diagnostic tools and potential treatments, improving the lives of over 250,000 Americans affected by the disorder.
A study by University of Illinois scientists reveals the FRG1 gene is crucial for angiogenesis, contributing to blood vessel growth and organization in the retina. The findings support the idea that FRG1 expression is a main cause of visual deficits associated with facioscapulohumeral muscular dystrophy.
Researchers successfully transferred a gene to produce a protein necessary for healthy muscle fiber growth, increasing muscle-fiber size and producing the needed protein for at least six months. The findings demonstrate the feasibility of gene therapy for treating limb-girdle muscular dystrophy and other muscle disorders.
Researchers at Children's National Medical Center and colleagues in Tokyo have achieved the first successful application of exon-skipping to curb Duchenne muscular dystrophy in dogs. The treatment uses synthetic DNA-like molecules called morpholinos to skip over mutated gene parts, showing promise for humans with this genetic disorder.
Scientists have developed a successful treatment for dogs with Duchenne muscular dystrophy using 'exon skipping' technology, which covers up genetic errors. The treatment involves injecting tailor-made DNA patches into the bloodstream, improving muscle functioning and reducing deterioration in skeletal muscles.
Researchers identified the location of genetic material responsible for producing nNOS, a critical component for muscle health. The discovery could lead to more effective gene therapy for Duchenne muscular dystrophy patients.
Researchers found that firefly luciferase tests can produce false positive results, which may impact the screening process. The study's findings suggest more work is needed to ensure the accuracy of the screening process.
Researchers found that ankyrin-B protein plays a vital role in stabilizing microtubules and anchoring dystrophin to the muscle membrane, preventing cellular damage and death. The study provides new insights into the underlying mechanisms of muscular dystrophy.
Researchers found that laminin-111 restored regenerative capacity in a mouse model for alpha 7 integrin congenital myopathy. The protein promotes muscle cell health and survival by interacting with the extracellular matrix.
Researchers at the University of Rochester Medical Center have identified several compounds that block unwanted RNA coupling, a key step in the disease. The discovery offers hope for developing a drug-like molecule to treat myotonic muscular dystrophy.
Researchers discovered that adding sarcospan to muscle cells improves protection against Duchenne muscular dystrophy, a condition caused by faulty anchoring of the dystrophin protein. Sarcospan coaxes utrophin, a dystrophin relative, to spread out on the muscle membrane, providing additional protection.
Researchers have found an effective way to deliver gene therapy, targeting both skeletal and cardiac muscle, with the potential to treat Duchenne muscular dystrophy. The therapy could be beneficial for patients by correcting electrocardiogram abnormalities in their hearts.
A University of Iowa study identifies a faulty signaling pathway that causes exercise-induced fatigue in mouse models of muscular dystrophy. The research suggests that targeting this pathway may lead to therapies for this type of fatigue. Viagra was shown to overcome the signaling defect and relieve the fatigue.
Agrin and MuSK don't directly communicate, but LRP4 serves as a bridge to initiate critical internal cell talk. This finding sheds light on the agrin-MuSK signaling pathway's role in muscular dystrophy.
The NIH has awarded $9 million to launch the first Senator Wellstone Muscular Dystrophy Cooperative Research Center (MD CRC) focusing on facioscapulohumeral muscular dystrophy (FSHD). The center will collaborate with patients, researchers, and pharmaceutical companies to study causes and potential treatments.
The project utilizes physiological information to develop more sophisticated assistive aids for individuals with neuromuscular diseases and musculoskeletal injuries. Researchers aim to create robotic orthoses that can aid patients with muscular dystrophy regain significant use of their limbs.
A multicenter study has identified risk factors for sudden death in people with myotonic dystrophy type 1, a common form of muscular dystrophy. The study found that patients with significant ECG abnormalities were at a 3.5 times higher risk of sudden death, while those with atrial arrhythmias had a 5 times higher risk.
Researchers at the University of Montreal have discovered a potential new treatment for cardiac complications in Duchenne muscular dystrophy patients. The study, published in the Proceedings of the National Academy of Sciences, shows that administering sildenafil protects the heart in mice with the disease.
Researchers have discovered the molecular basis of a form of muscular dystrophy by identifying c-FLIP and calpain-3 proteins as drug targets. The study found that people with limb-girdle muscular dystrophy lack the c-FLIP protein, which regulates muscle cell death.
Researchers tested Debio-025, an antiviral drug, on mice with muscular dystrophy and found it reduced mitochondrial swelling and cell death. The study suggests a new treatment strategy for Duchenne muscular dystrophy and may have implications for other degenerative disorders.
Researchers identified a protein called follistatin that could lead to new clinical treatments for musculoskeletal diseases, including Duchenne muscular dystrophy. Gene-delivery therapy involving FS treated hind leg muscles of mice, resulting in increased muscle mass and strength, well-tolerated for over two years.
Researchers at the University of Alabama at Birmingham found that PTC124 restored normal function in up to 29 percent of abnormal cystic-fibrosis protein cases. The drug works by rescuing faulty proteins that lead to illnesses, including cystic fibrosis and over 2,400 genetic diseases.
A new study suggests that myostatin inhibitors, currently under study for medical conditions and bodybuilding, may also increase the risk of small, brittle tendons making muscle injuries more likely. Researchers found that myostatin's absence led to shorter, stiffer tendons in mice.
A new clinical trial results in a proof-of-principle for personalized molecular medicine, with the potential to treat muscular dystrophies and other disorders. The treatment uses an 'exon-skipping' approach to restore dystrophin protein production in muscle tissue.
Researchers found that individuals with Type 1 myotonic muscular dystrophy overproduce the heart protein NKX2-5, yet experience similar cardiac problems. Reducing excessive NKX2-5 levels may protect against these issues, leading to potential diagnostic and therapeutic breakthroughs.
Researchers discovered microRNAs linked to 10 major muscular disorders, opening doors to new treatments. The study found that targeting specific microRNAs may slow muscle loss by addressing the underlying biological processes.
Researchers at Baylor College of Medicine found that increased levels of CUGBP1 contribute to myotonic dystrophy type 1 by altering splicing patterns in heart and skeletal muscle. The study also reveals the involvement of another RNA-binding protein, MBNL1, in regulating gene expression.
A recent study discovered that mice lacking the protein myostatin and overproducing follistatin have four times more muscle mass than normal mice. This finding offers new avenues for enhancing muscle growth in patients with muscular dystrophy and other wasting diseases.
A study published in Neurology found that daily steroid treatments increased the walking time of boys with Duchenne muscular dystrophy by 3.3 years and reduced the incidence of scoliosis. However, treatment was associated with a higher risk of vertebral and leg fractures.
A new class of treatment, PTC124, has been shown to restore muscle function in a mouse model of Duchenne muscular dystrophy by targeting a specific genetic defect. The drug allows the ribosome to read through a mutation and produce full-length dystrophin protein, enabling enough protein to be made to correct defects in the muscles.
Researchers at Dana-Farber Cancer Institute found that boosting a key muscle gene improved Duchenne muscular dystrophy symptoms in mice. The study suggests increasing PGC-1alpha levels could slow or reduce disease progression.
Researchers identify PGC-1alpha as a key genetic component and potential therapeutic target for Duchenne muscular dystrophy. Experimental elevation of PGC-1alpha improves DMD symptoms in mouse models, offering new therapeutic promise.
Researchers found that blocking TGF-beta activity with losartan restores normal muscle structure and function in genetically engineered mice with Marfan syndrome and Duchenne muscular dystrophy. The treatment improved strength, reduced fatigue, and restored muscle architecture.
Researchers discovered that caveolin-3 inhibits myostatin signaling, preventing muscle wasting. Additionally, elevated PTTG1 levels triggered mitotic mischief, causing aneuploidy in thyroid cancer cells. Understanding these mechanisms can lead to potential therapies for muscular dystrophy and thyroid cancer.
A study reveals that caveolin-3 helps prevent muscle wasting in muscular dystrophy by blocking myostatin signaling. Inhibiting myostatin rescued the muscle wasting in mice, suggesting a promising therapy for certain types of muscular dystrophy.
Researchers demonstrate that trichostatin A can counteract muscular dystrophy in mice by promoting muscle regeneration and upregulating follistatin, a key protein involved in muscle development. Further studies are needed to determine the effectiveness of the drug in larger animals before it can be tested in humans.
Researchers have found that a class of cancer drugs can restore skeletal muscle mass and prevent decline in muscular dystrophy. Treatment with histone deacetylase inhibitors like Trichostatin A improved muscle function and resistance to degeneration in dystrophic mice.
Researchers at the University of Virginia Health System have successfully reversed myotonic muscular dystrophy in mice by removing toxic RNA from muscle cells. The disease causes progressive muscle wasting and other symptoms in about 40,000 people worldwide.
A team of researchers has achieved a significant breakthrough in treating Duchenne muscular dystrophy by successfully transplanting healthy muscle cells into patients, showing promise for increasing the production of the missing protein dystrophin. The new clinical trials aim to further assess the treatment's effectiveness and measure ...
Dr. Liu has discovered a mechanism underlying immune system modulation of Multiple Sclerosis (MS) and will optimize therapy using NKT cells. The Muscular Dystrophy Association fellowship award supports her three-year research project.
Researchers used gene therapy to introduce a healthy copy of the dystrophin gene into mice with muscular dystrophy, repairing the entire muscle cell. The technique, developed by Michele Calos, has potential for long-term fixes for various genetic diseases.
Researchers have discovered a new muscle-building agent that increases muscle size by 60% in mice after just two weekly injections. The agent targets the myostatin protein and has shown promising results in mice with muscular dystrophy, suggesting potential for treating muscle-wasting diseases.
Two new research centers will explore new treatment strategies and biochemical pathways contributing to muscular dystrophy. Clinical trials and laboratory studies will focus on increasing muscle growth, inhibiting enzyme breakdown, and identifying genetic modifiers.